NEW MJ NEWS

AbbVie to Present at the Barclays Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 12:35 p.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-barclays-global-healthcare-conference-301765150.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

 Charlotte’s Web Holdings, Inc. (CWBHF) (CWEB) Earns NSF International’s Good Manufacturing Practice Registration

Charlotte’s Web Earns NSF International’s Good Manufacturing Practice Registration  Charlotte’s Web Holdings,…

$AFAI To Focus On Legal Marijuana Industry

AFAI To Focus On Legal Marijuana Industry; Name And Symbol Change To…

Innocan Pharma Corporation (INNPF) Announces Private Placement of Units at a 9% Prime Above Share Price

Innocan Pharma Announces Private Placement of Units at a 9% Prime Above…